


Supplementary Table S1. Characteristics of patients who underwent liver-directed surgery for NELM according to surgical approach.

		MILS (n = 13)	OLS (n = 39)	p
Gender ¹	Female	6 (46%)	24 (62%)	0.331
	Male	7 (54%)	15 (38%)	
Age (years) ²		57 (46 – 73)	60 (21 – 80)	0.664
BMI (kg/m ²) ²		25 (20 – 36)	25 (19 – 34)	0.715
ASA ¹	2	5 (38%)	27 (69%)	0.048
	3	8 (62%)	12 (31%)	
Localization of primary ¹	Pancreas	6 (46%)	17 (44%)	0.872
	Small intestine	7 (54%)	22 (56%)	
Appearance of metastases ¹	Synchronous	10 (77%)	28 (72%)	0.718
	Metachronous	3 (23%)	11 (28%)	
Indication ¹	Curative	5 (38%)	17 (44%)	0.746
	Debulking	8 (62%)	22 (56%)	
Duration of surgery (minutes) ²		285 (130 – 504)	265 (90 – 575)	0.767
Extent of surgery ¹	Major resection	3 (23%)	14 (36%)	0.636
	Minor resection	10 (77%)	25 (64%)	
Simultaneous resection of primary ¹		4 (31%)	19 (49%)	0.259
ICU ¹		11 (85%)	33 (85%)	1.0
Length of ICU stay ²		1 (0 – 6)	1 (0 – 35)	0.702
Length of hospital stay ²		10 (7 – 20)	12 (6 – 132)	0.100
90-day complications ¹		6 (46%)	18 (46%)	1.0


90-day major complications ¹		5 (38%)	15 (38%)	1.0
90-day mortality ¹		0 (0%)	0 (0.0%)	1.0
Resection of primary ¹		12 (92%)	39 (100%)	0.080
Grading primary ¹	G1	4 (31%)	14 (36%)	0.214
	G2	8 (61%)	25 (64%)	
	G3	1 (8%)	0 (0%)	
Grading hepatic metastases ¹	G1	4 (31%)	15 (38%)	0.813
	G2	8 (61%)	20 (52%)	
	G3	1 (8%)	4 (10%)	
R status ¹	R0	4 (31%)	17 (44%)	0.179
	R1	1 (8%)	0 (0%)	
	R2	8 (61%)	22 (56%)	
Neoadjuvant therapy ¹		3 (23%)	19 (49%)	0.143
Adjuvant therapy ¹		11 (85%)	30 (77%)	0.678
>1 adjuvant therapy modalities ¹		6 (46%)	20 (51%)	0.749
>2 adjuvant therapy modalities ¹		3 (23%)	12 (31%)	0.596

¹ Count (percentage); ² Median (range); NELM, neuroendocrine liver metastases; MILS, Minimally invasive liver surgery; OLS, open liver surgery; BMI, Body Mass Index; ASA, American Society of Anesthesiologists; ICU, Intensive Care Unit




Number at risk		0	24	48	72	96	120	144
siNET	29	10	4	2	2	1	0	0
pNET	23	10	2	0	0	0	0	0

(a)




Number at risk		0	24	48	72	96	120	144
siNET	29	16	11	5	2	1	0	0
pNET	23	15	9	6	5	2	0	0


(b)




(c)



(d)



(e)



(f)

Supplementary Figure S1. Disease / Progression free and overall survival according to primary tumor site, grading of primary tumor and hepatic metastases. Different primary tumor sites did not show significant differences in (a) DFS / PFS nor (b) OS; (c) DFS / PFS and (d) OS did not differ significantly between primary tumor gradings focusing on G1 and G2 tumors; Different gradings of hepatic metastases had no significant effect on (e) DFS / PFS nor (f) OS. Survival analyses were performed using Kaplan-Meier method.